)
Edge17 Oct 2025
A Castle in the Sky: The Story of Oracle
Oracle's journey from database innovator to disciplined enterprise backbone, now shaping the AI buildout with a standardized cloud infrastructure.
Molecular Partners (MOLN) investor relations material
Molecular Partners H1 2025 earnings summary
Complete event summary combining all related documents: earnings call transcript, report, and slide presentation.H1 2025 earnings summary25 Aug, 2025
Executive summary
Clinical-stage biotech advancing DARPin-based targeted cancer therapies, focusing on radio-DARPins and next-gen immune cell engagers, with operations in Switzerland and the US and global partnerships, notably with Orano Med.
Pipeline includes MP0712 (targeted radiotherapy for SCLC/NECs), MP0726 (ovarian cancer), and MP0533 (tetra-specific T-cell engager for AML), with significant progress in clinical and preclinical programs.
Strategic review completed, extending cash runway into 2028, with a workforce reduction of up to 24% and appointment of Martin Steegmaier, PhD, as CSO effective October 2025.
Expanded radiotherapy partnership with Orano Med to co-develop up to ten 212Pb programs.
Accepted request from NuMeRI to provide MP0712 for compassionate imaging use in South Africa.
Financial highlights
Cash and cash equivalents and short-term time deposits totaled CHF 114 million as of June 30, 2025, ensuring funding into 2028.
Net cash used in operations was CHF 30.2 million in H1 2025.
Operating loss of CHF 33.5 million in H1 2025, including CHF 2.6 million restructuring charge.
Net result was a loss of CHF 37.2 million, compared to a loss of CHF 26.4 million in H1 2024.
FY 2025 operating expense guidance confirmed at CHF 55–65 million, including CHF 7 million in non-cash costs.
Outlook and guidance
MP0712 IND filing expected Q3 2025; Phase 1 study to start in H2 2025, with initial safety data in H1 2026.
Early imaging data for MP0712 anticipated in Q4 2025.
Initial data from MP0533 amended dosing (cohort 9) expected Q4 2025; cohort 10 to start soon; combo trials planned for 2026.
MP0726 and Switch-DARPin programs to progress with initial clinical data expected in 2026.
Preclinical update on CD3 Switch-DARPin T cell engager at SITC 2025.
MP0533: Regulatory discussions for next steps
Orano Med partnership: 212Pb supply capabilities
Headcount reduction impact on cash runway?
Partial view of Summaries dataset, powered by Quartr API
Research faster. Power your platform.
Next Molecular Partners earnings date
Q3 202528 Oct, 2025
Next Molecular Partners earnings date
Q3 202528 Oct, 2025
The essential earnings season companion
The #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Live calls and transcripts
Listen to earnings calls, CMDs, investor conferences, and more – with a podcast-like experience.
Find what you need faster
Search for any keyword across all transcripts simultaneously.
Easily store key findings
Capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Your watchlist. Your dashboard.
Follow the companies that matter to you. Get a personalized feed with real-time updates.
Be the first to know
Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned.
Consensus estimates
Access analyst consensus estimates, valuation multiples, and revenue segments splits.
All IR material in one place
The easiest way to stay updated during earnings season.
Global coverage
All events from public companies. Live and recorded.
Just click and listen
No webcast links. No manual registrations.
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
)
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
)
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
excellent app, it gives me free access to company earnings calls and annual reports. I also love the convenience of calls being available offline so I can listen in whilst doing other things and even when internet or WiFi isn't available.
Leroy DaleyApp Store
One of the very few apps you could call perfect. If something was to add to it, maybe the share price of the company when you search for it, but it's already excellent.
Eferix Drawings Google Play
This is genuinely one of the cleanest and fastest finance apps out there to track the market.
anuj283App Store
I can't remember the last time an app had such a positive impact on my investment process.
)
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
I can't remember the last time an app had such a positive impact on my investment process.
@ankurshah47_ x.com
Love the app! Quartr makes it really easy to keep track of earnings calls. It also includes the reports and slides to make it easier to follow along.
Amina0781App Store
Quartr is amazing, no way around it. It is the best right now for earnings calls, presentations, and the like.
@theshortbearx.com
Related articles
)
Company Research17 Oct 2025
Beneath the Surface: A Conversation with Epiroc CEO Helena Hedblom
Legacy, innovation, and leading one of Sweden's most influential industrial companies into a new era.
)
Investor Relations14 Oct 2025
Boost Your Earnings Season Strategy With Real‑Time Alerts
Quartr Pro provides real time alerts, trend analysis and live coverage, giving analysts and investors instant insights to act faster in earnings.
Frequently asked questions
Molecular Partners AG is a clinical-stage biopharmaceutical company headquartered in Schlieren, canton of Zürich, Switzerland. Founded in 2004 by researchers from the University of Zürich, the company specializes in the development of a novel class of custom-built protein therapeutics known as Designed Ankyrin Repeat Proteins (DARPins). These DARPins are versatile and potent small-protein therapies with applications across various disease areas, including oncology, immuno-oncology, ophthalmology, and infectious diseases. Molecular Partners has established itself in the biotechnology industry by leveraging its DARPin platform to create therapies that aim to surpass the limitations of current treatment options. Molecular Partners AG's shares are listed on the SIX Swiss Exchange and the Nasdaq.
Quartr provides global coverage of all investor relation material from public companies.
Mobile app: Research anytime, anywhere with the #1 app for live earnings calls, transcripts, analyst estimates, and more. All for free.
Desktop (Quartr Pro): The leading platform for qualitative research, used daily by top firms and financial institutions.
Quartr API: Build custom solutions powered by live earnings calls, live transcripts, filings and reports, slide presentations, and more.
Yes, the Quartr mobile app is free on both iOS and Android.
Yes. Quartr provides global, industry-leading live coverage of company events such as regular earnings calls, capital markets days, M&A announcements, and investor conferences. Live with zero delays. Just click and listen.
Yes, capturing important takeaways is as simple as it gets. Even during your lunch run or commute.
Yes. Follow the companies that matter to you. Get a personalized feed with real-time updates, a tailored earnings calendar, and instant alerts when earnings calls go live.
Yes. Set keyword alerts for any company, product, or competitor. Get notified the moment they're mentioned, regardless of who's talking.
Explore our global coverage